First-in-human stage III/IV melanoma clinical trial of immune priming agent IFx-Hu2.0.
Markowitz J, Shamblott M, Brohl AS, Sarnaik AA, Eroglu Z, Khushalani NI, Dukes CW, Chamizo A, Bastawrous M, Garcia ET, Delhawi A, Chen PL, De Aquino DB, Sondak VK, Tarhini AA, Kim Y, Lawman P, Pilon-Thomas S.
Markowitz J, et al. Among authors: chen pl.
Mol Cancer Ther. 2024 Apr 24. doi: 10.1158/1535-7163.MCT-23-0652. Online ahead of print.
Mol Cancer Ther. 2024.
PMID: 38657233